Recently Featured

Biopharma R&D Pipeline Shrinks for First Time in 30 Years: Report

April 15, 2026
The biopharma research and development pipeline has contracted for the first time in three decades, as reported by Citeline. This decline marks a significant shift in the pharmaceutical landscape, where the number of drugs in development has seen a notable decrease. Factors contributing to this trend may include methodological changes in data collection and analysis,…

Hydrogel-Based Axon Model Improves Early Testing for MS Remyelination Therapies

April 15, 2026
Researchers at University College London (UCL) have developed a hydrogel-based axon model that significantly enhances the study of myelin formation and the efficacy of remyelination therapies for multiple sclerosis (MS). This innovative model addresses a critical gap in drug development, as many candidates that show promise in traditional rigid lab settings fail in human trials…

Medicare Advantage Plans Gain $18.6 Billion as Federal Star Ratings Measures are Reduced

April 15, 2026
The Trump administration’s recent decision to reduce the number of quality and care measures for Medicare Advantage plans will result in an additional $18.6 billion directed towards health insurers over the next decade. This regulatory change, announced by the Centers for Medicare and Medicaid Services (CMS), marks a significant shift in the financial landscape for…

AI In Silico Multi-Omics Technique Cuts Therapeutic Development Costs

April 15, 2026
Bringing a drug from discovery through clinical trials takes too long and is too expensive, with preclinical costs alone estimated at $15 to $100 million. Employing artificial intelligence (AI) early in the process can lower those costs dramatically. Jayson Uffens, CTO and chairman of GATC Health, emphasizes that while AI enhances the capabilities of researchers,…

Ongoing Cases